Moshe joined Moebius in December 2015, and brings with him over 15 years of business experience. Prior to joining Moebius, Moshe spent 7 years at Novartis in the US and Latin America where he held positions of increasing responsibility in business development & licensing, sales, marketing and commercial management. Prior to Novartis, Moshe served as a consultant for PricewaterhouseCoopers. Moshe earned an MBA from INSEAD, and has a bachelors in business & management from Yeshiva University in New York.
Dr. Yaniv Dolev,
VP Research & Development
Yaniv founded Moebius in 2008 and served as the company’s CEO from its foundation until December 2015. Yaniv was responsible for the development and successful clinical trial of MM-II, and led the company through a series of fundraising rounds. Yaniv trained as a Veterinary Surgeon at the Faculty of Veterinary Science, National University of La Plata, Argentina, where he specialized in equine orthopedics. He earned an M.B.A. from the School of Macro-Economic Studies, Buenos Aires, Argentina.
Dr. Maty Ayal-Hershkovitz,
VP Quality Assurance
Maty joint Moebius in September 2013, and brings with her over 20 years of experience in pharmaceutical biotechnology. Maty is an expert in biopharmaceuticals process development, quality systems establishment, inspections and training, complex technologies transfer and CMC. Prior to joining Moebius, Maty held positions of Process Development Manager, Head of Technology Transfer, Quality Assurance and Regulatory Affairs Manager. Maty has a Ph.D. in Biological Chemistry from the Hebrew University in Jerusalem and spent 4 years as a post-doctoral fellow in the Beckman Research Institute of City of Hope, California.
Dr. Ronny Pinkus,
VP Manufacturing & Operations
Ronny joined Moebius in January 2017, and brings with him over 20 years of experience in pharmaceuticals and biotechnology. Ronny is an expert in process development, scale-up and CMC (Chemistry, Manufacturing & Controls). He has significant expertise as it relates to GMP issues in pharmaceutical manufacturing for various types of products, including small molecules, recombinant proteins, glycans, pegylation and viruses for ethical and bio-similar Drugs. Prior joining Moebius, Ronny held several managing positions at Interpharm, Merck Serono, Teva Pharmaceuticals Industries and InSight Biopharmaceuticals. Ronny holds a PhD from the Weizmann Institute and an MBA from the Polytechnic Institute of New York.
Dr. Gadi Sarfati,
Senior Director, Pre-Clinical Development
Gadi joined Moebius in January 2017, and brings with him considerable experience in pharmaceutical drug development. Prior to joining Moebius, Gadi held the position of Director of Pharmaceutical Development at Chiasma, a biotech company leveraging its proprietary technology platform designed to enable the intestinal absorption of molecules that would otherwise have limited intestinal bioavailability. Prior to Chiasma, Gadi spent 7 years in the innovative R&D division at Teva Pharmaceuticals Industries, where he held positions of CMC Project Leader and Pharmaceutical Operations Team Leader. Gadi has a Ph.D. in Biotechnology Engineering from the Ben Gurion University of the Negev, Beer-Sheva, Israel.
Prof. Chezy Barenholz,
Inventor & Board Member
Yechezkel “Chezy” Barenholz, Ph.D. is the head of the Laboratory of Membrane and Liposome Research at the Department of Biochemistry, at the Hebrew University, Hadassah Medical School, Jerusalem, Israel. Dr. Barenholz is a world renowned specialist in lipids and membranes, and is on the Editorial Boards of Chemistry and Physics of Lipids and the Journal of Liposome Research. He is one of the key inventors of DOXIL, a liposomal formulation of doxorubicin for cancer treatment, marketed by Johnson & Johnson.
Mr. Uri Ben-Or,
Uri brings over a decade of broad experience in corporate finance, accounting, M&A transactions, IPO’s and operations. He provides his services to Moebius through CFO Direct, a company which he founded and is the Chief Executive Officer. Prior to founding CFO Direct he served as the VP Finance of Glycominds, a leading biotechnology company, and as CFO of a spin-off from Telrad Networks, where he led all the corporate finance activities, fund raising and legal aspects of the company. He also served as a Corporate Controller at Menorah Capital Markets and as an Auditor at Price Waterhouse Coopers. Mr. Ben-Or holds a BA degree in Business from the College of Administration, and a MBA degree from the Bar Ilan University. He is a Certified Public Accountant.